Renal Status Influences PCI Outcomes

April 2013
Renal & Urology News;Apr2013, Vol. 12 Issue 4, p28
The article reports on the study which found that greater degrees of renal impairment are associated with increasingly adverse 90-day outcomes among patients undergoing primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). It shows a significant increase in the pre-specified 90-day composite outcome of death, shock, and heart failure. It indicates that patients with more severe chronic kidney disease (CKD) had significantly longer delays to PCI.


Related Articles

  • Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. Juurlink, David N.; Gomes, Tara; Lipscombe, Lorraine L.; Austin, Peter C.; Hux, Janet E.; Mamdani, Muhammad M. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;9/5/2009, Vol. 339 Issue 7720, p562 

    The article discusses a study which assessed the influence of rosiglitazone and pioglitazone administration on the risks of heart failure, myocardial infarction and death in patients with diabetes. The study included diabetic patients, aged 66 years and above in Ontario, who were treated with...

  • TZDs linked with increased risk for heart problems, death. Haigh, Christen // Endocrine Today;1/10/2008, Vol. 6 Issue 1, p8 

    This article discusses research being done on the side effects of rosiglitazone in patients with diabetes. It references a study by L. L. Lipscombe et al., published in a 2007 issue of the "Journal of the American Medical Association." The study found that rosiglitazone was linked to an...

  • Daunorubicin/doxorubicin.  // Reactions Weekly;5/16/2009, Issue 1252, p19 

    The article presents case reports of two patients who experienced cardiogenic shock and refractory hypoxaemia after receiving daunorubicin and/or doxorubicin and both subsequently died. Patient 1, a 46-year-old woman, was treated with doxorubicin for follicular non-Hodgkin's lymphoma, and four...

  • Pioglitazone: better cardiac safety profile than rosiglitazone.  // Reactions Weekly;8/29/2009, Issue 1267, p4 

    The article discusses a study of the association of pioglitazone with cardiac events in elderly diabetic patients in Canada. It relates the proportion of patients who died or were hospitalised with myocardial infarction or heart failure during the follow-up period. It concludes that pioglitazone...

  • Another Study Implicates Avandia. Elliott, William T. // Clinical Oncology Alert;Feb2008 Pharmacology Watch, Vol. 24, p1 

    The article reports on a study which linked the rosiglitazone drug Avandia from GlaxoSmithkline with an increased risk of heart failure, cardiovascular events and mortality as compared to other oral hypoglycemic agents based on data from health care databases Ontario. Primary outcome in older...

  • TZDs linked to adverse CV outcomes in older DM patients.  // Reactions Weekly;1/5/2008, Issue 1183, p3 

    This article reports that researchers from the Institute for Clinical Evaluative Sciences in Canada has found that thiazolidinedione given in elderly patients with diabetes mellitus are more likely to experience congestive heart failure or myocardial infarction, thereby increasing the...

  • Biologics offer targeted treatment, warrant caution. Petrou, Ilya // Dermatology Times;May2007 Psoriasis Supplement, Vol. 28, ps34 

    The article focuses on the adverse effects of using biologics in treating patients with moderate-to-severe psoriasis. According to doctor Mark Lebwohl, the use of these drugs has demonstrated high efficacy in treating psoriasis, but caution must be taken because of the side effects of...

  • Pulmonary Hypertension and Isolated Right Heart Failure Complicating Amiodarone Induced Hyperthyroidism Wong, Sean-Man; Tse, Hung-Fat; Siu, Chung-Wah // Heart, Lung & Circulation;Mar2012, Vol. 21 Issue 3, p163 

    Hyperthyroidism is a common side effect encountered in patients prescribed long-term amiodarone therapy for cardiac arrhythmias. We previously studied 354 patients prescribed amiodarone in whom the occurrence of hyperthyroidism was associated with major adverse cardiovascular events including...

  • Rosiglitazone or pioglitazone in type 2 diabetes? De Vries, Corinne S.; Russell-Jones, David L. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;9/5/2009, Vol. 339 Issue 7720, p324 

    The article discusses research on the safety of thiazolidinediones, rosiglitazone and pioglitazone, in type 2 diabetes. It references the study "Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study," by D. N. Juurlink and colleagues,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics